ArticleThe Journal of infectious diseases2024
Results of a Nationally Representative Seroprevalence Survey of Chikungunya Virus in Bangladesh.
Article in The Journal of infectious diseases, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
8 citing papers in PubMed.
- Seroprevalence of chikungunya virus in Colombo, Sri Lanka before the 2025 outbreak and implications for population susceptibility.medRxiv : the preprint server for health sciences · 2026Article
- A brief review of chikungunya fever: From molecular virology to countermeasures.Infectious medicine · 2026Review
- Seroprevalence of Dengue, Chikungunya, and Zika Viruses Among Febrile Patients in Dhaka, Bangladesh: A Hospital-Based Cross-Sectional Study.Pathogens (Basel, Switzerland) · 2025Article
- Acute febrile illness in remote and rural communities: Perspectives of health providers and managers in Chattogram, Bangladesh.SSM - health systems · 2025Article
- Epidemiological and antigenic inferences from serological cross-reactivity among arboviruses.Science translational medicine · 2025Article
- The Return of Chikungunya in Bangladesh in 2024: Implications for Future Outbreaks.The American journal of tropical medicine and hygiene · 2025Article
- The reappearance of Chikungunya virus in Bangladesh, 2024.IJID regions · 2025Article
- Facile quantitative diagnostic testing for neutralizing antibodies against Chikungunya virus.BMC infectious diseases · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
Abstract
There is an increasing global burden from chikungunya virus (CHIKV). Bangladesh reported a major epidemic in 2017, but it was unclear whether there had been prior widespread transmission. We conducted a nationally representative seroprevalence survey in 70 randomly selected communities immediately before the epidemic. We found that 69 of 2938 sampled individuals (2.4%) were seropositive to CHIKV. Seropositivity to dengue virus (adjusted odds ratio, 3.13 [95% confidence interval, 1.86-5.27]), male sex (0.59 [.36-.99]), and community presence of Aedes aegypti mosquitoes (1.80 [1.05-3.0]7) were significantly associated with CHIKV seropositivity. Using a spatial prediction model, we estimated that across the country, 4.99 (95% confidence interval, 4.89-5.08) million people had been previously infected. These findings highlight high population susceptibility before the major outbreak and that previous outbreaks must have been spatially isolated.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.